RxDoctor Payments DataLook up a doctor →

Robert Rubenstein, MD

Neurology · Silverdale, WANPI 1437185279

Payments from drug & device makers

$98,589in general payments, 2019–2025

Across 921 payments — averaging $107.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$83K
  • Sanofi$1K
  • Novartis$1K
  • Teva Pharmaceuticals USA, Inc.$999
  • AstraZeneca$856
  • EMD Serono, Inc.$789
  • plus $11K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)139$82,614
Sanofi40$1,150
Novartis58$1,002
Teva Pharmaceuticals USA, Inc.33$999
AstraZeneca(2 entities)38$856
EMD Serono, Inc.46$789
Lilly USA, LLC39$733
Biogen24$699
Pfizer45$699
Acadia Pharmaceuticals Inc41$637
UCB, Inc.29$516
Amgen(2 entities)25$503
Argenx US, Inc.25$480
Genentech USA, Inc.18$438
Lundbeck LLC22$409
Eisai Inc.13$358
Acorda Therapeutics, Inc20$353
Amneal Pharmaceuticals LLC13$341
Johnson & Johnson(2 entities)28$337
SK Life Science, Inc.15$319
TG Therapeutics, Inc.14$313
Merz Pharmaceuticals, LLC11$310
Neurocrine Biosciences, Inc.13$309
Impel Pharmaceuticals Inc.13$285
Neurelis, Inc.11$279
CSL Behring14$251
Bristol Myers Squibb12$246
Alnylam Pharmaceuticals Inc.11$229
Upsher-smith Laboratories LLC11$218
Boston Scientific11$193
MDD US Operations, LLC5$152
Biohaven Pharmaceutical Holding Company Ltd.12$128
Kyowa Kirin, Inc.6$116
Ipsen Biopharmaceuticals, Inc4$94
GE HealthCare4$76
Amylyx Pharmaceuticals, Inc.4$74
Catalyst Pharmaceuticals, Inc.4$72
Supernus Pharmaceuticals, Inc.4$71
Grifols USA, LLC3$60
Takeda Pharmaceuticals U.S.A., Inc.2$58
Avanir Pharmaceuticals, Inc.3$57
Corium, LLC3$57
Otsuka America Pharmaceutical, Inc.2$56
Avion Pharmaceuticals3$53
Jazz Pharmaceuticals Inc.2$52
Bausch Health US, LLC2$46
Livanova USA, Inc.2$44
Vertical Pharmaceuticals, LLC2$44
Azurity Pharmaceuticals, Inc.2$43
Vanda Pharmaceuticals Inc.1$33
Assertio Therapeutics, Inc.2$32
Currax Pharmaceuticals LLC2$30
E.r. Squibb & Sons, L.L.C.2$27
Sunovion Pharmaceuticals Inc.1$25
Sumitomo Pharma America, Inc.1$24
Biohaven Pharmaceuticals, Inc.1$24
Cala Health, Inc.1$23
Banner Life Sciences, LLC1$20
Springworks Therapeutics, Inc.1$20
Octapharma USA, Inc.1$19

How this compares

$98,589 in reported general payments places this provider in the 90th percentile of 418 neurology providers in Washington.

See all neurology providers in Washington →

Medicare billing

Part B allowed, 2024
$394,486
Medicare patients
1,019
Services billed
31,726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Silverdale

See the full list for Washington →

Where these figures come from

Is this you, or does something look wrong? →